Skip to content

Faculty Member

Paul Arora Hon. BSc, MSc, PhD

Email Address(es)
paul.arora(at)utoronto.ca
Office Phone
6474074867
Office Address
Cytel 3rd Floor. 1 University Avenue. Toronto, ON M5J 2P1
Website(s)
LinkedIn
Division(s)/Institute(s)
Epidemiology Division
Position
Adjunct Lecturer
SGS Status
Associate (Restricted) Member
Currently Accepting Doctoral Students?
Yes

Research Interests

  • Comparative Effectiveness Methods
  • Causal Inference Methods
  • Target Trial Emulation
  • Machine Learning
  • Graphical Models
  • Oncology
  • Pharmacoepidemiology
  • Infectious diseases
  • Statistical methods for longitudinal analysis
  • Knowledge translation
  • Real-world data
  • Adaptive clinical trials
  • Bayesian Networks
  • Bayesian statistics

Education & Training History

2008 – 2013

Doctor of Philosophy (Epidemiology)

Dalla Lana School of Public Health, University of Toronto

Thesis: Characterizing the HIV epidemic in India and quantifying the impact of targeted interventions.

Other Affiliations

Vice President, Advanced Epidemiology

Cytel

1 University Avenue

Toronto, ON

M5J 2P1

Primary Teaching Responsibilities

CHL5412H – Communicable Disease Epidemiology, Co-Director

CHL5401H – Epidemiologic Methods 1, Guest Lecturer, Faculty Tutor

CHL5004H – Introduction to Public Health, Faculty Tutor

CHL5418H – Scientific Overviews in Epidemiology, Faculty Tutor

Professional Summary & Appointments

  • April 2014 – Current: Assistant Professor (Status-only), Division of Epidemiology, Dalla Lana School of Public Health. University of Toronto
  • April 2015 – June 2016: Epidemiologist & Visiting Scholar. Centre for Global Child Health, Peter Gilgan Centre for Research and Learning. The Hospital for Sick Children
  • April 2014 – June 2015: Executive Committee, Co-chair (with Prof S. Jaglal). Canadian Society for Epidemiology and Biostatistics Toronto 2015 Biennial Conference.
  • January 2013 – March 2014: Canadian Society for Epidemiology and Biostatistics – Secretary

Representative Publications

Gilmar Reis, M.D., Ph.D., Eduardo A.S. Moreira Silva, M.D., Ph.D., Daniela C. Medeiros Silva, M.D., Ph.D., Lehana Thabane, Ph.D., Vitoria H.S. Campos, Thiago S. Ferreira, M.D., Castilho V.Q. Santos, Ana M.R. Nogueira, M.D., Ana P.F.G. Almeida, M.D., Leonardo C.M. Savassi, M.D., Ph.D., Adhemar D. Figueiredo-Neto, M.D., Ph.D., Ana C.F. Dias, Ph.D., et al., for the TOGETHER Investigators*.  Early Treatment with Pegylated Interferon Lambda for Covid-19. February 9, 2023. N Engl J Med 2023; 388:518-528. DOI: 10.1056/NEJMoa2209760

Boyne DJ, Brenner DR, Gupta A, Mackay E, Arora P, Wasiak R, Cheung WY, Hernán MA. Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Annals of Epidemiology. 2023 Feb 1;78:28-34.

Nsanzimana S, Gupta A, Uwizihiwe JP, Haggstrom J, Dron L, Arora P, Park JJ. The Need for a practical approach to evaluate the effectiveness of COVID-19 vaccines for low-and middle-income countries. The American Journal of Tropical Medicine and Hygiene. 2021 Sep;105(3):561.

Ramagopalan S, Gupta A, Arora P, Thorlund K, Ray J, Subbiah V. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer. JAMA Netw Open. 2021;4(11):e2134299. doi:10.1001/jamanetworkopen.2021.34299

Wilkinson S, Gupta A, Scheuer N, et al. Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data. JAMA Netw Open. 2021;4(10):e2126306. doi:10.1001/jamanetworkopen.2021.26306

Nsanzimana, S., Gupta, A., Uwizihiwe, J. P., Haggstrom, J., Dron, L., Arora, P., & Park, J. (2021). The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries. The American journal of tropical medicine and hygiene105(3), 561–563. https://doi.org/10.4269/ajtmh.21-0482

Dewidar, O., Riddle, A., Ghogomu, E., Hossain, A., Arora, P., Bhutta, Z. A., … & Wells, G. A. (2021). PRIME-IPD SERIES Part 1. The PRIME-IPD tool promoted verification and standardization of study datasets retrieved for IPD meta-analysis. Journal of clinical epidemiology136, 227-234.

Gupta, A., Arora, P., Brenner, D., Vanderpuye-Orgle, J., Boyne, D. J., Edmondson-Jones, M., … & Wu, E. (2021). Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clinical Cancer Informatics5, 326-337.